You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 10, 2025

CLINICAL TRIALS PROFILE FOR PEPCID RPD


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Pepcid Rpd

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00256841 ↗ Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy Withdrawn Clinical Oncology Research Associates Phase 1/Phase 2 2005-09-01 The study is designed for patients with non small cell lung cancer whose cancer is too advanced and therefore cannot be operated with the goal of completely removing the cancer. At this stage of the disease, most patients cannot be cured from the disease, however, treatment can help to live longer and better by keeping the cancer under control. For that purpose, patients traditionally receive radiation therapy or chemotherapy or both treatments in succession. Recently, the administration of both treatment methods given concurrently showed somewhat better results when compared to successive administration. In some studies the drug Taxotere together with radiation performed well in keeping the cancer better under control. Combination of the drug Taxotere together with a compound called 5-FU either as continuous infusion or in its oral form of a pill called "Xeloda" enhanced its anti cancer activity substantially. One goal of this study is to investigate how much of the combination can be given in conjunction with chest radiation. Using X-rays, the study will also evaluate how much shrinkage of the cancer is caused by this treatment directly at the tumor site and other areas where the cancer may have also spread. In this study the radiation will be given on only one day per week in two sessions, rather than divided over five days per week (Monday through Friday) as it is more commonly used. However, both schedules have been found to be equally effective. The treatment program will use increasing doses of the 5-FU medication, either as infusion or as pill to find the highest dose that is tolerated. Once the highest tolerated dose is determined, subsequent patients who will be enrolled will continue to be treated at that dose level. The dose of the drug Taxotere will remain the same throughout. Hypothesis: Our previous research suggests that the combination of Taxotere and 5-FU given together with weekly chest radiation will provide a more convenient form of treatment than the conventional approach and also be at least similar in its efficacy.
NCT00451880 ↗ Study of XL281 in Adults With Solid Tumors Completed Exelixis Phase 1 2007-02-01 The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer tolerate XL281. This study will also determine how the body reacts to XL281 when it is taken with and without food, and with and without Pepcid (famotidine), a drug that inhibits stomach acid production.
NCT00557349 ↗ Ulcer Prevention Study in Post Gastric Bypass Patients Completed University of Missouri-Columbia Phase 4 2006-11-01 This research is to determine which medication, Zegerid (Omeprazole/Sodium Bicarbonate) or Pepcid AC (Famotidine), works best at reducing the chance that a patient will get an ulcer after gastric bypass surgery.
NCT01067066 ↗ A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma Terminated Cortice Biosciences, Inc. Phase 1 2010-02-03 The goal of the Phase I portion of this study is to find the highest tolerable dose of TPI 287 that can be given in combination with Temodar (temozolomide) to patients with metastatic melanoma. The goal of the Phase II portion of this study is to learn if TPI 287, given in combination with temozolomide, can control metastatic melanoma. The safety of this combination will also be studied. NOTE: Study stopped before progressing to Phase II portion.
NCT01067066 ↗ A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma Terminated M.D. Anderson Cancer Center Phase 1 2010-02-03 The goal of the Phase I portion of this study is to find the highest tolerable dose of TPI 287 that can be given in combination with Temodar (temozolomide) to patients with metastatic melanoma. The goal of the Phase II portion of this study is to learn if TPI 287, given in combination with temozolomide, can control metastatic melanoma. The safety of this combination will also be studied. NOTE: Study stopped before progressing to Phase II portion.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pepcid Rpd

Condition Name

Condition Name for Pepcid Rpd
Intervention Trials
Covid19 5
Healthy 5
COVID-19 5
COVID-19 Virus Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pepcid Rpd
Intervention Trials
COVID-19 7
Respiration Disorders 3
Infections 3
Coronavirus Infections 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pepcid Rpd

Trials by Country

Trials by Country for Pepcid Rpd
Location Trials
United States 42
India 2
Australia 1
Jordan 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pepcid Rpd
Location Trials
Texas 10
New York 3
Florida 3
Arizona 3
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pepcid Rpd

Clinical Trial Phase

Clinical Trial Phase for Pepcid Rpd
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pepcid Rpd
Clinical Trial Phase Trials
Completed 13
Recruiting 8
Not yet recruiting 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pepcid Rpd

Sponsor Name

Sponsor Name for Pepcid Rpd
Sponsor Trials
M.D. Anderson Cancer Center 5
Leidos Life Sciences 3
Bristol-Myers Squibb 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pepcid Rpd
Sponsor Trials
Other 21
Industry 19
U.S. Fed 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Pepcid RPD: Clinical Trials, Market Analysis, and Projections

Clinical Trials and Efficacy of Pepcid RPD

Mechanism of Action

Pepcid RPD, which contains the active ingredient famotidine, is a histamine-2 (H2) receptor antagonist. It works by reducing the amount of acid produced in the stomach, thereby alleviating symptoms associated with gastroesophageal reflux disease (GERD), duodenal ulcers, and gastric ulcers[1].

Clinical Trial Outcomes

In controlled clinical trials, Pepcid RPD has demonstrated significant efficacy in various gastrointestinal conditions:

  • Duodenal Ulcers: Studies have shown that Pepcid RPD is effective in maintaining healed duodenal ulcers. In two double-blind, multicenter studies, the cumulative observed ulcer incidence within 12 months was significantly lower in patients treated with Pepcid RPD compared to those receiving placebo (23.4% vs 56.6% in the U.S. study and 35.7% vs 75.5% in the international study)[1].

  • Gastric Ulcers: Pepcid RPD has been shown to provide faster relief of daytime and nighttime pain in patients with active benign gastric ulcers. Although there was no significant difference in the proportion of patients whose pain was relieved by the end of the study, the time to complete relief was statistically shorter for those receiving Pepcid RPD[1].

  • Gastroesophageal Reflux Disease (GERD): In a U.S. study, Pepcid RPD 20 mg twice daily was superior to 40 mg once daily and placebo in providing symptomatic relief for GERD patients without endoscopic evidence of esophageal erosion or ulceration. Patients receiving Pepcid RPD experienced faster relief of daytime and nighttime heartburn and a greater percentage of complete relief of nighttime heartburn[1].

Market Analysis

Current Market Size and Growth

The acid reducer market, which includes drugs like Pepcid RPD, is substantial and growing. As of 2023, the global acid reducer market stands at approximately $23.1 billion and is projected to reach $40.3 billion by 2033, growing at a compound annual growth rate (CAGR) of 5.7%[2].

Market Segmentation

The market is segmented by type, form, availability, and distribution channel. Histamine-2 antagonists like Pepcid RPD are a significant segment within the acid reducer market.

  • Type: Histamine-2 antagonists and proton pump inhibitors (PPIs) are the primary types of acid reducers. H2 antagonists, including Pepcid RPD, offer an alternative for patients who do not respond well to PPIs[3].

  • Form: Acid reducers are available in various forms such as tablets, liquid, powder, and others. Tablets, which include Pepcid RPD, hold the largest market share[2].

  • Availability: The market is divided into over-the-counter (OTC) and prescription (Rx) drugs. OTC medications, which include many acid reducers, account for more than 50% of the market share due to their ease of access and consumer preference[2].

  • Distribution Channel: Online and offline channels contribute to the sales of acid reducers. The presence of online pharmacies and e-commerce platforms has significantly boosted sales, especially for OTC medications[2].

Regional Analysis

The North American market, in particular, is a significant segment for acid reducers. This region is expected to grow at a CAGR of 5.5% during the forecast period, driven by the high prevalence of GERD and peptic ulcer disease, as well as lenient regulations on OTC drugs[2].

Key Drivers and Restraints

  • Drivers: The growing geriatric population, increasing prevalence of GERD and other gastrointestinal disorders, and the adoption of sedentary lifestyles are key drivers of the market. Additionally, advancements in medical technology and the ease of availability of OTC medications contribute to market growth[2][5].

  • Restraints: Concerns over potential side effects, such as the link to dementia in the aging population, and the patent expiry of blockbuster drugs can act as restraints to the market[2][5].

Projections and Future Outlook

Market Growth

The acid reducer market, including Pepcid RPD, is expected to continue growing due to several factors:

  • Increasing Prevalence of GERD: The rising incidence of GERD and other gastrointestinal disorders will drive the demand for effective treatments like Pepcid RPD[5].

  • Advancements in Medical Technology: Precision medicine and other technological advancements will continue to improve treatment outcomes and patient adherence to prescribed regimens[2].

  • OTC Availability: The ease of access to OTC medications will continue to drive market growth, especially through online channels[2].

Competitive Landscape

Key players in the market, such as Merck & Co., AstraZeneca, and Takeda, are focusing on optimizing the use of their products and enhancing patient access. Collaborations with healthcare providers to ensure appropriate usage guidelines and raise awareness about potential side effects are also crucial for market growth[3][5].

Key Takeaways

  • Efficacy in Clinical Trials: Pepcid RPD has shown significant efficacy in treating duodenal ulcers, gastric ulcers, and GERD.
  • Market Size and Growth: The global acid reducer market is projected to grow from $23.1 billion in 2023 to $40.3 billion by 2033.
  • Market Segmentation: Histamine-2 antagonists like Pepcid RPD are a key segment within the acid reducer market.
  • Regional Growth: The North American market is expected to grow significantly due to high prevalence rates and lenient OTC regulations.
  • Drivers and Restraints: Growing geriatric population, increasing prevalence of GERD, and OTC availability drive the market, while concerns over side effects and patent expiries act as restraints.

FAQs

What is the primary mechanism of action of Pepcid RPD?

Pepcid RPD works by reducing the amount of acid produced in the stomach through its action as a histamine-2 (H2) receptor antagonist.

How effective is Pepcid RPD in treating duodenal ulcers?

Pepcid RPD has been shown to significantly reduce the cumulative observed ulcer incidence in patients with healed duodenal ulcers compared to placebo.

What is the projected growth rate of the acid reducer market?

The acid reducer market is expected to grow at a CAGR of 5.7% from 2023 to 2033.

Which region is expected to drive the growth of the acid reducer market?

The North American market is anticipated to grow at a CAGR of 5.5% during the forecast period, driven by high prevalence rates of GERD and lenient OTC regulations.

What are the key drivers of the acid reducer market?

The growing geriatric population, increasing prevalence of GERD, and the ease of availability of OTC medications are key drivers of the market.

Sources

  1. FDA Label for Pepcid: "PEPCID Tablets" - FDA.
  2. Acid Reducer Market Report: "Acid Reducer Market Size, Trends and Forecast 2023 to 2033" - Fact.MR.
  3. GERD Market Analysis: "Gastroesophageal Reflux Disease Market Estimated to Reach a CAGR of 1.21% during 2024-2034" - BioSpace.
  4. Famotidine Labeling Change: "Famotidine Labeling Change" - JAMA Network.
  5. GERD Therapeutics Market Report: "Global Gastroesophageal Reflux Disease Therapeutics Market Report 2023" - GlobeNewswire.

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.